Xencor Reports Second Quarter 2021 Financial Results August 4, 2021 -- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif.--(BUSINESS WIRE)--Aug. 4, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a review of recent business and portfolio highlights. "Xenco ...